Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires
polypharmacological treatment of the single conditions including type II diabetes …

Diabetic kidney disease (DKD) is the primary cause of chronic kidney disease around the
globe and is one of the main complications in patients with type 1 and 2 diabetes. The …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

The prevalence of obesity has increased dramatically during the past decades, which has
been a major health problem. Since 1975, the number of people with obesity worldwide has …

Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract
maladaptive cardiac changes triggered by diabetes in some but not all studies. We …

Diabetic kidney disease (DKD) is not only one of the main complications of diabetes, but
also the leading cause of the end-stage renal disease (ESRD). The occurrence and …

Despite recent therapeutic advances, chronic kidney disease (CKD) is one of the fastest
growing global causes of death. This illustrates limitations of current therapeutic approaches …

Roughly 3% of patients worldwide with a new diagnosis of type 2 diabetes mellitus (T2DM)
already have an overt nephropathy at diagnosis and about 20–30% of the remaining ones …

OBJECTIVE The objective of the current study was to assess the secular trends in the
prevalence of diabetes, prediabetes, and risk factors from two epidemiological surveys done …

In recent years, inhibitors of the sodium-glucose co-transporter 2 (SGLT2 inhibitors) have
been shown to have significant protective effects on the kidney and the cardiovascular …